SEC Filing Summary: Landec Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc.) on January 10, 2022. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The primary purpose of this report is to disclose the Company's scheduled presentation at the 2022 ICR Conference.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding a conference presentation and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing solely announces the upcoming investor conference presentation.
Guidance, Outlook, and Risks
The Company will present materials at the 2022 ICR Conference. These materials are attached as Exhibit 99.1. The filing explicitly states that the information in this Item 7.01 and the attached presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other Company filings. No specific guidance, risks, or contingencies are detailed within the text of this 8-K.
Key Facts for Investor Verification
- Verify the discrepancy between the requested company name (Lifecore Biomedical, Inc.) and the actual registrant (Landec Corporation).
- Review the attached Exhibit 99.1 (ICR Conference 2022 Presentation) for any forward-looking statements or financial outlook, as these are not included in the 8-K text itself.
- Note that the presentation materials are not legally "filed" with the SEC and carry different liability standards than formal filings.